Clinical Trials

Find a Trial

Trial Results

191 protocol(s) meet the specified criteria
04-30OPEN TO ACCRUAL
A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician?s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent
10PLK13OPEN TO ACCRUAL
Proleukin? Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
14-006OPEN TO ACCRUAL
CLINICAL VALIDATION OF A URINE-BASED ASSAY WITH GENOMIC AND EPIGENOMIC MARKERS FOR PREDICTING RECURRENCE DURING SURVEILLANCE FOR NON-MUSCLE INVASIVE BLADDER CANCER
4T-14-1OPEN TO ACCRUAL
Phase II trial of retroperitoneal lymph node dissection as first-line treatment for testicular seminoma with isolated retroperitoneal disease (1-2cm)
9812-11OPEN TO ACCRUAL
Laboratory Studies of Peripheral Blood and Bone Marrow Cells Isolated from Patients with Clonal Myeloid or Lymphoproliferative Disorders
A011104OPEN TO ACCRUAL
Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer
A011202OPEN TO ACCRUAL
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A011401OPEN TO ACCRUAL
RANDOMIZED PHASE III TRIAL EVALUATING THE ROLE OF WEIGHT LOSS IN ADJUVANT TREATMENT OF OVERWEIGHT AND OBESE WOMEN WITH EARLY BREAST CANCER
A011502OPEN TO ACCRUAL
A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR NODE POSTIVE HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL
A021501OPEN TO ACCRUAL
PREOPERATIVE EXTENDED CHEMOTHERAPY VS. CHEMOTHERAPY PLUS HYPOFRACTIONATED RADIATION THERAPY FOR BORDERLINE RESECTABLE ADENOCARCINOMA OF THE HEAD OF THE PANCREAS
A061402OPEN TO ACCRUAL
SOLITARY PLASMACYTOMA OF BONE: RANDOMIZED PHASE III TRIAL TO EVALUATE TREATMENT WITH ADJUVANT SYSTEMIC TREATMENT AND ZOLEDRONIC ACID VERSUS ZOLEDRONIC ACID AFTER DEFINITE RADIATION THERAPY
A081105OPEN TO ACCRUAL
RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF ERLOTINIB OR PLACEBO IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
A151216OPEN TO ACCRUAL
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
A221405/IBCSG48-POSITIVEOPEN TO ACCRUAL
A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy(POSITIVE)
ADP-0000-001OPEN TO ACCRUAL
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Non-Small Cell Lung Cancer (NSCLC)
APX-CLN-0011OPEN TO ACCRUAL
A Phase 1 Dose-escalation Study of APX3330 in Patients with Advanced Solid Tumors and a Dose-expansion Cohort of Patients with Advanced Ductal Adenocarcinoma of the Pancreas
ARRAY818-302OPEN TO ACCRUAL
The BEACON CRC Study (Binimetinib, Encorafenib, And Cetuximab COmbiNed to Treat BRAF-mutant ColoRectal Cancer): A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer
ASG-22CE-13-2OPEN TO ACCRUAL
A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4
B-016-001OPEN TO ACCRUAL
Clinical Assessment of Intraoperative Nerve Monitoring during Robot-assisted Laparoscopic Prostatectomy
BAY94-9343OPEN TO ACCRUAL
Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY 94-9343)in Patients with Mesothelin Expressing Advanced or Recurrent Malignancies
BBI608-201OPEN TO ACCRUAL
A Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies
BR-076OPEN TO ACCRUAL
A Randomized Phase II clinical trial assessing the Efficacy and Safety of MK-3475 ( pembrolizumab) in combination with carboplatin and gemcitabine in patients with metastatic triple negative breast cancer
BRE12-158OPEN TO ACCRUAL
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer
BTCRC-GI13-002OPEN TO ACCRUAL
An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients with Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002
BTCRC-GYN15-013OPEN TO ACCRUAL
Phase II Study of Pembrolizumab in Combination with Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma
BTCRC-LUN16-081OPEN TO ACCRUAL
Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
BTCRCLUN15-029OPEN TO ACCRUAL
A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor
C16-168OPEN TO ACCRUAL
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects
C16011OPEN TO ACCRUAL
A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
CABOZANTINIBOPEN TO ACCRUAL
NF-105: A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects with Neurofibromatosis Type 1 age 16-65 years
CANSTEM111POPEN TO ACCRUAL
A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma.
CC06-C-0213OPEN TO ACCRUAL
Tissue Procurement Protocol for the Development Therapeutics Clinic, National, Cancer Institution (NCI)
CC9078OPEN TO ACCRUAL
Phase I/IB Multi-Center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW2992)in Combination with Capecitabine for Advanced Solid Tumors and Pancretico- Biliary Cancers
CP-MGAH22-04OPEN TO ACCRUAL
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
CTMX-M-072-001OPEN TO ACCRUAL
AN OPEN-LABEL, DOSE-FINDING AND PROOF OF CONCEPT STUDY OF THE PD-L1 PROBODY THERAPEUTIC, CX-072, AS MONOTHERAPY AND IN COMBINATION WITH YERVOY (IPILIMUMAB) OR WITH ZELBORAF (VEMURAFENIB) IN ANTI-PD-1/PD-L1 INHIBITOR NAIVE SUBJECTS WITH ADVANCED OR RECURRENT SOLID TUMORS OR LYMPHOMAS
CTMX-M-2009-001OPEN TO ACCRUAL
A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors
E1Z11OPEN TO ACCRUAL
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
E2112OPEN TO ACCRUAL
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer
E4412OPEN TO ACCRUAL
A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma.
E4512OPEN TO ACCRUAL
A Phase III Double Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
EA5142OPEN TO ACCRUAL
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) ? A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
EAY131-C1/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
EAY131-C2/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
EAY131-L/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
EAY131-M/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
EAY131-Z1C/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
EAY131-Z1E/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
EAY131/MATCHOPEN TO ACCRUAL
Molecular Analysis for Therapy Choice (MATCH)
GCP-10100OPEN TO ACCRUAL
Evaluation of the TULSA-PRO MRI-Guided Transurethral Ultrasound Prostate Ablation Device in Patients with Localized Prostate Cancer: a Prospective, Single-Arm, Pivotal Clinical Study
GI15-225OPEN TO ACCRUAL
A Pilot Study of Pembrolizumab in Combination with Y90 Radioembolization in Subjects with Poor Prognosis Hepatocellular Carcinoma with Preserved Liver Function
GOG-0238OPEN TO ACCRUAL
A Randomized Trial of Pelvic Irradiation with or Without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
GOG-0263OPEN TO ACCRUAL
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy
GOG-3009OPEN TO ACCRUAL
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV (Advaxis Immunotherapy 2 prevent CERVical recurrence)
GOG-3011OPEN TO ACCRUAL
A RANDOMIZED, OPEN LABEL PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MIRVETUXIMAB SORAVTANSINE (IMGN853) VERSUS INVESTIGATOR?S CHOICE OF CHEMOTHERAPY IN ADULTS WITH FOLATE RECEPTOR a-POSITIVE ADVANCED EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CANCER OR PRIMARY FALLOPIAN TUBE CANCER
GS-US-339-1559OPEN TO ACCRUAL
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Subjects with Acute Myeloid Leukemia (AML)
GS-US-339-1560OPEN TO ACCRUAL
A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL)
GU115/I6A-MC-CBBDOPEN TO ACCRUAL
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer
GU14-188OPEN TO ACCRUAL
Phase Ib/II Study of Neoadjuvant Pembrolizumab (MK-3475) with Gemcitabine-Cisplatin (cisplatin eligible) or Gemcitabine (cisplatin-ineligible) in Subjects with T2-4aN0M0 Urothelial Cancer
I9L-MC-JZCAOPEN TO ACCRUAL
A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination with Anti- PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors
INCB39110-301OPEN TO ACCRUAL
GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticostaroids for the Treatment of First-Line Acute Graft-Versus-Hose Disease.
INCB62079-101OPEN TO ACCRUAL
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
IUCRO-0031OPEN TO ACCRUAL
Molecular and Pathological Correlates of Treatment Outcome in Patients with Thymoma and Thymic Carcinoma
IUCRO-0042OPEN TO ACCRUAL
Blood Drawing for Study of Peripheral Blood T-Lymphocytes and Other Parameters in patients with Metastatic Melanoma and Renal Cell Cancer with Spontaneous Regression
IUCRO-0049OPEN TO ACCRUAL
Immunologic, Genetic, Molecular, and Pathological Correlates with Clinical and Treatment Outcome in Patients with Renal Cell Carcinoma
IUCRO-0209OPEN TO ACCRUAL
The Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center: A Collection and Storage of Biological Specimens Intended for use in the Elucidation of Breast Carcinogenesis
IUCRO-0216OPEN TO ACCRUAL
Indiana University Simon Cancer Center Hematologic Malignancies Tissue Bank
IUCRO-0280OPEN TO ACCRUAL
IU Simon Cancer Center Tissue Bank
IUCRO-0309OPEN TO ACCRUAL
IU Pancreatic Lesion Tissue/Fluid Bank
IUCRO-0373OPEN TO ACCRUAL
A Path Analysis Modeling of the Interaction of AXII and/or AXIIR with the Changes in Cytokines and Myeloma Bone Disease (The Cytokine Protocol)
IUCRO-0381OPEN TO ACCRUAL
Role of Microenvironmental-Derived AXII in Myeloma Bone Disease: An Exploratory Model
IUCRO-0419OPEN TO ACCRUAL
A Phase II Trial of Prostaglandin E2 Inhibition, using Meloxicam, plus Filgrastim for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma and Non-Hodgkin?s Lymphoma
IUCRO-0429OPEN TO ACCRUAL
Resilience Profile for Adolescents and Young Adults with Cancer and Parents
IUCRO-0450OPEN TO ACCRUAL
Concordance of sensitivity and resistance testing between Cisplatin and Ifosfamide in Soft Tissue Sarcomas: A Retrospective Review
IUCRO-0454OPEN TO ACCRUAL
Molecular Phenotyping of Pancreatic Cancer Cachexia: A Bridge to Personalized Targeted Therapy
IUCRO-0459OPEN TO ACCRUAL
Investigating A Novel Modifiable Factor Affecting Renal Function After Partial Nephrectomy: Cortical Renorrhaphy
IUCRO-0474OPEN TO ACCRUAL
Evaluation Of A Laparoscopic High Intensity Focused Ultrasound Probe For The Ablation Of Small Renal Masses
IUCRO-0476OPEN TO ACCRUAL
A Study of the Effect of Sirolimus Levels on Incidence of Hepatic Sinusoidal Obstructive Syndrome
IUCRO-0485OPEN TO ACCRUAL
Genomic Signatures of Primary Tumor Predict Outcome in Testicular Germ Cell Tumor
IUCRO-0486OPEN TO ACCRUAL
A Pilot Study Evaluating a Novel Biodynamic Imaging (BDI) Method in Predicating Response to Chemotherapy in Locoregional Esophageal Cancer
IUCRO-0495OPEN TO ACCRUAL
Creation of a Pancreatic Cancer Outcome Database with Blood Storage
IUCRO-0498OPEN TO ACCRUAL
Role of Osteocytes in Myeloma Bone Disease
IUCRO-0499OPEN TO ACCRUAL
Identifying a predictive biomarker for taxane in patients with metastatic Castration Resistant Prostate Cancer (mCRPC)
IUCRO-0508OPEN TO ACCRUAL
Phase Ib Study of the Hypomethylating Drug SGI-110 plus Cisplatin in Relapsed Refractory Germ Cell Tumors
IUCRO-0513OPEN TO ACCRUAL
Testicular Cancer Pilot Survey
IUCRO-0514OPEN TO ACCRUAL
Collection Of Specimens And Clinical Data To Create A Biorepository For Metastatic Breast Cancer
IUSCC-0515OPEN TO ACCRUAL
Pilot study to determine the utility of mesoscopic (i.e. between microscopic and macroscopic) imaging system for assisting tumor and tumor margin detection
IUSCC-0522OPEN TO ACCRUAL
Phase II Trial of Inhibition Dipeptidyl Peptidase (DPP)-4 with Sitagliptin for the Prevention of Acute Graft versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
IUSCC-0523OPEN TO ACCRUAL
Perioperative pelvic floor muscle training may improve recovery of continence in men with localized prostate cancer undergoing robot-assisted radical prostatectomy.
IUSCC-0534OPEN TO ACCRUAL
COLLECTION OF SPECIMENS AND CLINICAL DATA TO CREATE A BIOREPOSITORY FOR PRECISION GENOMICS
IUSCC-0544OPEN TO ACCRUAL
A Pilot Mixed-Methods Study of Induction Related Decision Making in Newly-Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia
IUSCC-0551OPEN TO ACCRUAL
A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination with Vorinostat in Patients with Advanced Renal or Urothelial Cell Carcinoma
IUSCC-0552OPEN TO ACCRUAL
A Pilot Study Evaluating a Novel Magneto-Fluidic System for Ultra-High Throughput Detection of Circulating Tumor Cells in Patients with Metastatic and Loco-regional Urothelial Bladder Cancer
IUSCC-0555OPEN TO ACCRUAL
Inhibiting fatty acid synthase to improve efficacy of neoadjuvant chemotherapy.
IUSCC-0556OPEN TO ACCRUAL
Pilot study of the effect of weight loss on breast tissue and blood biomarkers in women at increased risk for breast cancer
IUSCC-0564OPEN TO ACCRUAL
Kidney Cancer Services (KCS) Registry and Bio-Bank
IUSCC-0565OPEN TO ACCRUAL
Pilot study of respiratory-gated stereotactic body radiation therapy for boderline resectable, unresectable, or recurrent/residual adenocarcinoma of the pancreas or periampullary region.
IUSCC-0568OPEN TO ACCRUAL
Phase II Study of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
IUSCC-0574OPEN TO ACCRUAL
A PHASE I/II STUDY TO EVALUATE THE SAFETY, PHARMACODYNAMICS AND EFFICACY OF ATEZOLIZUMAB IN COMBINATION WITH ENTINOSTAT AND BEVACIZUMAB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
IUSCC-0579OPEN TO ACCRUAL
Salvage High Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors: Indiana University Experience 1990-2015
IUSCC-0580OPEN TO ACCRUAL
Blood Based Recurrence Detection for Patients with Lung Cancer Receiving Radiation Therapy
IUSCC-0581OPEN TO ACCRUAL
Photoacoustic Imaging in Human Prostate Cancer
IUSCC-0582OPEN TO ACCRUAL
ANALYSIS OF IMMUNE STATUS FOLLOWING HYPOFRACTIONATED VS. CONVENTIONALLY FRACTIONATED RADIATION THERAPY
IUSCC-0584OPEN TO ACCRUAL
COLLECTION OF SPECIMENS AND CLINICAL DATA TO CREATE A BIOREPOSITORY FOR THE GENITOURINARY ONCOLOGY PROGRAM
IUSCC-0587OPEN TO ACCRUAL
Sequelae of Treatment in Survivors of Testicular Cancer Creation of a Non-exposed Comparison Group for the Platinum Study
IUSCC-0588OPEN TO ACCRUAL
Glycosylation of exosomes in prostate and urothelial carcinoma
IUSCC-0590OPEN TO ACCRUAL
iMETX (Individualized Metabolic RX): a pilot study of an environmental intervention to increase energy expenditure among breast cancer survivors
IUSCC-0597OPEN TO ACCRUAL
A phase II trial of cabozantinib and erlotinib for patients with EGFR and c-Met co-expressing metastatic pancreatic adenocarcinoma
IUSCC-0600OPEN TO ACCRUAL
Clinical Stage I Testicular Cancer: Difficult Decisions
IUSCC-0602OPEN TO ACCRUAL
Telephone Support Program for Advanced Lung Cancer Patients and their Family Caregivers
IUSCC-0604OPEN TO ACCRUAL
A Pilot Study to Assess Theragnostically Planned Liver Radiation with Functional DVH Analysis to Optimize Individualized Radiation Therapy
IUSCC-0605OPEN TO ACCRUAL
Evaluating dose de-escalation in whole brain radiation therapy with simultaneous integrated boost for patients with brain metastases
IUSCC-0608OPEN TO ACCRUAL
T-Cell Leukemia/Lymphoma Biorepository
IUSCC-0611OPEN TO ACCRUAL
Retrospective Analysis of Patients with Metastatic Germ Cell Tumor at Indiana University
IUSCC-0612OPEN TO ACCRUAL
Mindfulness to Enhance Quality of Life and Support Advance Care Planning (MEANING): A Randomized Controlled Pilot Trial for Adults with Metastatic Cancer and Their Family Caregivers
IUSCC-0613OPEN TO ACCRUAL
An initial safety study of Gedatolisib plus PTK7-ADC for metastatic triple-negative breast cancer
IUSCC-0614OPEN TO ACCRUAL
A pilot feasibility study of sipuleucel-T vs. sipuleucel-T and low-protein diet in patients with metastatic castrate-resistant prostate cancer (CRPC)
IUSCC-0615OPEN TO ACCRUAL
Pilot Ex-Vivo Investigation of an Experimental Beta Probe for Assessment and Guidance of Prostate Cancer Resection
IUSCC-0616OPEN TO ACCRUAL
A Prospective Feasibility Study Investigating Primary Preventive Ability of Massage Therapy of Paclitaxel-Induced Peripheral Neuropathy in Patients with Newly Diagnosed Breast Cancer Scheduled to Undergo a Paclitaxel Based Regimen
IUSCC-0617OPEN TO ACCRUAL
Examination of the informed consent process as experienced by patients who have undergone a chemoembolization, radioembolization or transjugular intrahepatic portosystemic shunt (TIPS) procedure
IUSCC-0621OPEN TO ACCRUAL
Pilot Feasibility Study of Changes in Gene Regulation and DNA Methylation Following Music Therapy
IUSCC-0623OPEN TO ACCRUAL
A retrospective review of clinical, radiographic, radiation-treatment related, and biological factors associated with pneumonitis in patients treated with chemoradiation followed by pembrolizumab: a companion study to HCRN LUN 14-179
IUSCC-0624OPEN TO ACCRUAL
Phase I/II trial evaluating five fraction SABR dose escalation for early stage Squamous Cell Carcinoma of the Lung
IUSCC-0625OPEN TO ACCRUAL
Computerized Cognitive Training in Breast Cancer Survivors
IUSCC-0630OPEN TO ACCRUAL
COLLECTION OF SPECIMENS AND CLINICAL DATA TO CREATE A BIOREPOSITORY AND REGISTRY FOR INFLAMMATORY BREAST CANCER
IUSCC-0632OPEN TO ACCRUAL
Pilot Study to Examine Correlation of Nab-Paclitaxel/Gemcitabine Pharmacokinetics with Cachexia
IUSCC-0634OPEN TO ACCRUAL
Detection of single nucleotide variants in circulating tumor DNA of patients with metastatic castration resistant prostate cancer
IUSCC-0645OPEN TO ACCRUAL
Description of Cardiotoxicity Associated with Sunitinib in Renal Cell Carcinoma
J13104OPEN TO ACCRUAL
A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer (PBI 3.0)
LCCC1317OPEN TO ACCRUAL
Genotype-directed Phase II Study of Irinotecan Dosing in Metastatic Colorectal Cancer (mCRC) Patients Receiving FOLFIRI + Bevacizumab
MK-3475-412OPEN TO ACCRUAL
A randomized phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma (KEYNOTE-412)
MK-3475-629OPEN TO ACCRUAL
A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)
MS100015-0019OPEN TO ACCRUAL
An Open-label, Phase I, Dose Escalation Trial of Methionine Aminopeptidase 2 Inhibitor M8891 in Subjects with Advanced Solid Tumors
MS200770-0001OPEN TO ACCRUAL
A Phase I, Open-label, Uncontrolled, Multicenter, Dose-escalation Study of M3541 in Combination with Palliative Radiotherapy in Subjects with Solid Tumors
NEOD001-OLE251OPEN TO ACCRUAL
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects with Light Chain (AL) Amyloidosis who were previously enrolled in Study NEOD001-201 (PRONTO)
NKTR16-214-02OPEN TO ACCRUAL
A PHASE 1/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-214 AND NIVOLUMAB IN PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES
NRG-GI001OPEN TO ACCRUAL
Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
NSABP-B-51OPEN TO ACCRUAL
A Randomized Phase III Clinical Trial Evaluating post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotehrapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.
NSABP-B-55/BIG6-13OPEN TO ACCRUAL
A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
NSMM-5001OPEN TO ACCRUAL
A Global, prospective, non-interventional, observation study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT-MM study
PCYC-1140-IMOPEN TO ACCRUAL
A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD)
PHO-CIBMTR-DELGADO-13TLECOPEN TO ACCRUAL
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
PHO-COG-CROOP-ADVL1212OPEN TO ACCRUAL
ADVL1212, A Phase 1 Study of Crizotinib (IND# 105573) in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
PHO-COG-CROOP-ADVL1217OPEN TO ACCRUAL
ADVL1217, A Phase 1 Study of MK-1775(IND# 116495) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children with Diffuse Intrinsic Pontine Gliomas
PHO-COG-FALLON-AALL05B1OPEN TO ACCRUAL
A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
PHO-COG-FALLON-AALL08B1OPEN TO ACCRUAL
Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
PHO-COG-FALLON-AALL0932OPEN TO ACCRUAL
Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
PHO-COG-FALLON-AALL1131OPEN TO ACCRUAL
AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
PHO-COG-FALLON-AALL1231OPEN TO ACCRUAL
AALL1231 A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
PHO-COG-FALLON-AALL1331OPEN TO ACCRUAL
Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
PHO-COG-FALLON-AAML1031OPEN TO ACCRUAL
AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD
PHO-COG-FALLON-AAML1331OPEN TO ACCRUAL
A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid
PHO-COG-FALLON-ACCL1033OPEN TO ACCRUAL
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
PHO-COG-FALLON-ACNS0332OPEN TO ACCRUAL
Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Subjects
PHO-COG-FALLON-ACNS0831OPEN TO ACCRUAL
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
PHO-COG-FALLON-AEWS07B1OPEN TO ACCRUAL
A Children's Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens
PHO-COG-FALLON-AEWS1031OPEN TO ACCRUAL
A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
PHO-COG-FALLON-AEWS1221OPEN TO ACCRUAL
Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
PHO-COG-FALLON-AHEP0731OPEN TO ACCRUAL
Treatment of Children with All Stages of Hepatoblastoma
PHO-COG-FALLON-ALTE03N1OPEN TO ACCRUAL
Key Adverse Events Following Childhood Cancer
PHO-COG-FALLON-ALTE07C1OPEN TO ACCRUAL
ALTE07C1, Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
PHO-COG-FALLON-ALTE11C1OPEN TO ACCRUAL
ALTE11C1, Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma
PHO-COG-FALLON-ANBL00B1OPEN TO ACCRUAL
Neuroblastoma Biology Studies
PHO-COG-FALLON-ANBL1221OPEN TO ACCRUAL
A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma
PHO-COG-FALLON-AREN03B2OPEN TO ACCRUAL
Renal Tumors Classification, Biology, and Banking Study
PHO-COG-FALLON-D9902OPEN TO ACCRUAL
A Group Wide Protocol for Collecting and Banking Pediatric Cancer Research Specimens. An Intergroup Rhabdomyosarcoma Study Group Protocol
PHO-IU-SHIH-FATIGUEOPEN TO ACCRUAL
Assessing Fatigue Experienced by Pediatric Patients with Intracranial Neoplasms
PHO-LILLY-CROOP-ADVL1416OPEN TO ACCRUAL
A PHASE 1 STUDY OF RAMUCIRUMAB, A HUMAN MONOCLONAL ANTIBODY AGAINST THE VASCULAR ENDOTHELIAL GROWTH FACTOR-2 (VEGFR-2) RECEPTOR IN CHILDREN WITH REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS
PHO-MILL-DELG-1209009655OPEN TO ACCRUAL
A phase I study evaluating the addition of bortezomib to an established acute graft versus host disease (aGVHD) prophylaxis regimen in pediatric allogeneic hematopoietic stem cell transplant (alloHSCT) patients
PRE0109OPEN TO ACCRUAL
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer [AFT-05]
R-223OPEN TO ACCRUAL
Retrospective Analysis of Clinical Benefit from Radium 223 in Castrate Resistant Prostate Cancer
RADY-BTG-TANN-HIDA/0603OPEN TO ACCRUAL
Assessment of the effect of Y90 therapy on non-target/background liver
RADY-ECOG-WESTPHAL-EA1151OPEN TO ACCRUAL
Tomosynthesis Mammographic Imaging Screening Trial (TMIST) EA1151
RSRB45410OPEN TO ACCRUAL
Genetic Susceptibility and Biomarkers of Platinum-Related Toxicities
RTOG-0848OPEN TO ACCRUAL
A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (PH II-R) and Chemoradiation (PHIII) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
S1416OPEN TO ACCRUAL
PHASE II RANDOMIZED PLACEBO-CONTROLLED TRIAL OF CISPLATIN WITH OR WITHOUT ABT-888 (VELIPARIB) IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER AND/OR BRCA MUTATION-ASSOCIATED BREAST CANCER
S1500OPEN TO ACCRUAL
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
S1505OPEN TO ACCRUAL
A RANDOMIZED PHASE II STUDY OF PERIOPERATIVE mFOLFIRINOX VERSUS GEMCITABINE/NAB-PACLITAXEL AS THERAPY FOR RESECTABLE PANCREATIC ADENOCARCINOMA
S1609OPEN TO ACCRUAL
DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS
SARC024OPEN TO ACCRUAL
SARC024: A blanket protocol to study oral regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewing?like sarcomas
STU00077147OPEN TO ACCRUAL
Impact of Genetic Variants on Failure of Active Surveillance for Prostate Cancer
SURG-CLINGEN-ROBB-NOVAOPEN TO ACCRUAL
Evaluation of the Performance of the Clinical Genomics Colvera Test in the Detection of Disease Recurrence in Patients Diagnosed with Colorectal Cancer
SURG-DUKE-CEPPA-VACOPEN TO ACCRUAL
A Randomized Phase II Evaluation of Negative Pressure Wound Therapy for Reduction of Postoperative Surgical Site Infection in Patients Undergoing Colorectal and Hepatopancreatobiliary Surgery
SURG-ETHICON-ROBB-ENSEALOPEN TO ACCRUAL
A Prospective, Multi-Center Evaluation of the ENSEAL X1 Large Jaw Tissue Sealer
SURG-LIFEB-FAJARDO-LSOPEN TO ACCRUAL
Efficacy and Safety of LifeSeal Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
TBCRC034OPEN TO ACCRUAL
The incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in patients diagnosed with Flat Epithelial Atypia (FEA) or Intraductal Papilloma without Atypia (IPWA) by Core Needle Biopsy
TBCRC035OPEN TO ACCRUAL
Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II study with Pharmacodynamics Markers
TBCRC037OPEN TO ACCRUAL
A Trial of Endocrine Response in Women with Invasive Lobular Breast Cancer
TBCRC038OPEN TO ACCRUAL
DIVERSITY IN THE TUMOR GENOME AND MICROENVIRONMENT AS DRIVERS OF DCIS PROGRESSION
TBCRC040OPEN TO ACCRUAL
Plasma Tumor DNA and Pathologic Complete Response in Early-Stage, High-Risk Breast Cancer
TC-UT-03-POPEN TO ACCRUAL
A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel on Ablation of Upper Urinary Tract Urothelial
WO29636OPEN TO ACCRUAL
A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA AFTER SURGICAL RESECTION